Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 132,900 shares, a drop of 7.9% from the November 15th total of 144,300 shares. Currently, 3.1% of the company’s stock are short sold. Based on an average daily volume of 232,800 shares, the days-to-cover ratio is presently 0.6 days.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets reduced their price target on shares of Alzamend Neuro from $50.00 to $35.00 and set a “buy” rating for the company in a report on Monday, November 11th.

Alzamend Neuro Price Performance

ALZN opened at $1.19 on Monday. The business’s 50-day moving average price is $1.45 and its two-hundred day moving average price is $2.66. Alzamend Neuro has a 1 year low of $1.06 and a 1 year high of $15.06.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.